Biological Agents in Familial Mediterranean Fever Focusing on Colchicine Resistance and Amyloidosis

被引：9

作者：

Sozeri, Betul ^{[1
]}

Kasapcopur, Ozgur ^{[2
]}

机构：

[1] Ege Univ, Fac Med, Dept Pediat, Izmir, Turkey

[2] Istanbul Univ, Cerrahpasa Med Fac, Dept Pediat, Istanbul, Turkey

来源：

CURRENT MEDICINAL CHEMISTRY | 2015年 / 22卷 / 16期

关键词：

Colchicine resistance; Familial Mediterranean fever; therapy; SUBCLINICAL INFLAMMATION; PERIODIC SYNDROME; INTERFERON-ALPHA; TURKISH PATIENTS; DOUBLE-BLIND; CANAKINUMAB; ARTHRITIS; EFFICACY; PROTEIN; TRIAL;

D O I：

10.2174/0929867322666150311152300

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Familial Mediterranean fever (FMF) is the most common hereditary autoinflammatory syndrome. FMF is caused by mutations in the MEFV gene which encodes the pyrin protein. FMF is characterized by sporadic, paroxysmal attacks of fever and serosal inflammation, lasting 1-3 days. Patients may develop renal amyloidosis. Colchicine prevents attacks and renal amyloidosis. 5% to 10% of the patients with FMF are resistant or intolerant to colchicine. Colchicine resistant patients may receive biological therapies. Anti-interleukin-1 drugs are the most important agents of biological treatments. In this review, colchicine resistance and treatment options will be evaluated.

引用

页码：1986 / 1991

页数：6

共 50 条

[21] Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
Yucel, Burcu Bozkaya
Aydog, Ozlem
Nalcacioglu, Hulya
Yilmaz, Aysegul
FRONTIERS IN PEDIATRICS, 2021, 9
[22] Canakinumab treatment in four children with colchicine resistant familial mediterranean fever
Ozkan, Solmaz
Atas, Bulent
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2017, 67 (06) : 945 - 947
[23] A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever
Alice Corsia
Sophie Georgin-Lavialle
Véronique Hentgen
Eric Hachulla
Gilles Grateau
Albert Faye
Pierre Quartier
Linda Rossi-Semerano
Isabelle Koné-Paut
Orphanet Journal of Rare Diseases, 12
[24] Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
Sener, Seher
Cam, Veysel
Batu, Ezgi Deniz
Kasap Cuceoglu, Muserref
Balik, Zeynep
Aliyev, Emil
Bayindir, Yagmur
Basaran, Ozge
Bilginer, Yelda
Ozen, Seza
RHEUMATOLOGY, 2023, 62 (11) : 3700 - 3705
[25] Treatment options in colchicine resistant familial Mediterranean fever patients: Thalidomide and etanercept as adjunctive agents
Seyahi, E.
Ozdogan, H.
Celik, S.
Ugurlu, S.
Yazici, H.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2006, 24 (05) : S99 - S103
[26] Pulmonary amyloidosis in familial mediterranean fever
Sahan, C.
Cengiz, K.
ACTA CLINICA BELGICA, 2006, 61 (03) : 147 - 151
[27] Colchicine treatment in children with familial Mediterranean fever
Özkaya, N
Yalçinkaya, F
CLINICAL RHEUMATOLOGY, 2003, 22 (4-5) : 314 - 317
[28] Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever?
Erden, A.
Batu, E. D.
Sari, A.
Sonmez, H. E.
Armagan, B.
Demir, S.
Firat, E.
Bilginer, Y.
Bilgen, S. A.
Karadag, O.
Kalyoncu, U.
Kiraz, S.
Ertenli, I.
Ozen, S.
Akdogan, A.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (06) : S97 - S102
[29] Appendectomy history is associated with severe disease and colchicine resistance in adult familial Mediterranean fever patients
BodakcI, Erdal
Yasar Bilge, Nazife Sule
AtaS, Nuh
Armagan, Berkan
Satis, Hasan
Sari, Alper
Bilici Salman, Reyhan
Yardimci, Gozde Kubra
Babaoglu, Hakan
Kilic, Levent
Akif Ozturk, Mehmet
Goker, Berna
Haznedaroglu, Seminur
Kalyoncu, Umut
Tufan, Abdurrahman
Kasifoglu, Timucin
TURKISH JOURNAL OF MEDICAL SCIENCES, 2021, 51 (04) : 1706 - 1711
[30] Colchicine treatment in children with familial Mediterranean fever
N. Özkaya
F. Yalçınkaya
Clinical Rheumatology, 2003, 22 : 314 - 317

← 1 2 3 4 5 →